Search results
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 6 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 3 days agoIt enables early interactions between the FDA and sponsors to facilitate accelerated approval and...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 4 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
Morningstar· 2 days agoBy Ben Glickman Sobi North America said it had received fast track designation from U.S. regulators for its potential treatment for Macrophage Activation Syndrome, a complication of rheumatic diseases. The Waltham, Mass.-based affiliate
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX...
FOX 23 News Albany· 5 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Calliditas Q1 report, January - March 2024
FOX 59 Indianapolis· 3 days agoNet sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety ...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...
Benzinga· 3 days agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 3 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
NBC 10 - FOX 14 Monroe· 2 days agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 ...
